Protalix Biotherapeutics Inc (PLX) — Cash Flow-to-Debt Ratio
Protalix Biotherapeutics Inc (PLX) has a Cash Flow-to-Debt Ratio of 0.06x as of December 2025, meaning its operating cash flow of $2.03 Million could theoretically repay 0% of its total liabilities ($34.12 Million) in one year. See Protalix Biotherapeutics Inc (PLX) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Protalix Biotherapeutics Inc Cash Flow-to-Debt Ratio (1996–2025)
Historical debt coverage capacity for Protalix Biotherapeutics Inc across 30 annual periods. Also explore how fast is Protalix Biotherapeutics Inc growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Protalix Biotherapeutics Inc (1996–2025)
Year-by-year debt coverage analysis for Protalix Biotherapeutics Inc. For market capitalisation and broader financial context, see Protalix Biotherapeutics Inc (PLX) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.35x | $-11.99 Million | $34.12 Million | ▼ -222.4% |
| 2024 | 0.29x | $8.67 Million | $30.21 Million | ▲ +1208.2% |
| 2023 | -0.03x | $-1.32 Million | $50.87 Million | ▲ +93.1% |
| 2022 | -0.38x | $-25.00 Million | $66.43 Million | ▼ -191.6% |
| 2021 | -0.13x | $-10.29 Million | $79.70 Million | ▲ +53.1% |
| 2020 | -0.27x | $-26.11 Million | $94.97 Million | ▼ -64.3% |
| 2019 | -0.17x | $-19.36 Million | $115.71 Million | ▼ -146.4% |
| 2018 | -0.07x | $-7.74 Million | $114.01 Million | ▲ +29.7% |
| 2017 | -0.10x | $-9.99 Million | $103.51 Million | ▲ +72.3% |
| 2016 | -0.35x | $-32.10 Million | $92.20 Million | ▼ -23.8% |
| 2015 | -0.28x | $-24.28 Million | $86.38 Million | ▼ -28.7% |
| 2014 | -0.22x | $-29.28 Million | $134.07 Million | ▲ +0.1% |
| 2013 | -0.22x | $-30.65 Million | $140.28 Million | ▼ -2924.7% |
| 2012 | 0.01x | $635.00K | $82.08 Million | ▲ +102.6% |
| 2011 | -0.30x | $-23.57 Million | $77.88 Million | ▲ +40.2% |
| 2010 | -0.51x | $-38.46 Million | $76.05 Million | ▼ -194.2% |
| 2009 | 0.54x | $44.45 Million | $82.79 Million | ▲ +121.7% |
| 2008 | -2.48x | $-16.02 Million | $6.46 Million | ▼ -5.6% |
| 2007 | -2.35x | $-10.45 Million | $4.45 Million | ▼ -24.7% |
| 2006 | -1.88x | $-5.09 Million | $2.70 Million | ▼ -89.5% |
| 2005 | -0.99x | $-72.47K | $72.93K | ▲ +58.3% |
| 2004 | -2.39x | $-168.12K | $70.47K | ▼ -37.6% |
| 2003 | -1.73x | $-136.68K | $78.82K | ▲ +6.5% |
| 2002 | -1.85x | $-146.59K | $79.07K | ▲ +81.9% |
| 2001 | -10.22x | $-789.43K | $77.28K | ▼ -10683.7% |
| 2000 | -0.09x | $-53.11K | $560.61K | ▲ +96.9% |
| 1999 | -3.07x | $-1.41 Million | $459.36K | ▼ -378.0% |
| 1998 | -0.64x | $-909.52K | $1.42 Million | ▼ -1831.8% |
| 1997 | -0.03x | $-247.92K | $7.47 Million | ▼ -500.7% |
| 1996 | -0.01x | $-40.57K | $7.34 Million | — |